Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
In the Large-Cap Pharmaceuticals industry, AbbVie, Novartis, Pfizer, Sanofi and Bayer are worth retaining amid macro pressure and rising innovation.
NORTH CHICAGO, Ill. , June 16, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) did not meet the primary endpoint of overall survival (OS) with a hazard ratio (HR) of 0.908; stratified log-rank, p=0.3772.
![]() ABBV In 4 weeks Estimated | Quarterly | $1.64 Per Share |
![]() ABBV 2 months ago Paid | Quarterly | $1.64 Per Share |
![]() ABBV 5 months ago Paid | Quarterly | $1.64 Per Share |
![]() ABBV 8 months ago Paid | Quarterly | $1.55 Per Share |
![]() ABBV 11 months ago Paid | Quarterly | $1.55 Per Share |
![]() ABBV 12 Apr 2024 Paid | Quarterly | $1.55 Per Share |
23 Jul 2025 (37 Days) Date | | - Cons. EPS | - EPS |
24 Apr 2025 Date | | - Cons. EPS | - EPS |
31 Jan 2025 Date | | 2.26 Cons. EPS | 2.16 EPS |
30 Oct 2024 Date | | 2.92 Cons. EPS | 3 EPS |
25 Oct 2024 Date | | 2.95 Cons. EPS | - EPS |
![]() ABBV In 4 weeks Estimated | Quarterly | $1.64 Per Share |
![]() ABBV 2 months ago Paid | Quarterly | $1.64 Per Share |
![]() ABBV 5 months ago Paid | Quarterly | $1.64 Per Share |
![]() ABBV 8 months ago Paid | Quarterly | $1.55 Per Share |
![]() ABBV 11 months ago Paid | Quarterly | $1.55 Per Share |
![]() ABBV 12 Apr 2024 Paid | Quarterly | $1.55 Per Share |
23 Jul 2025 (37 Days) Date | | - Cons. EPS | - EPS |
24 Apr 2025 Date | | - Cons. EPS | - EPS |
31 Jan 2025 Date | | 2.26 Cons. EPS | 2.16 EPS |
30 Oct 2024 Date | | 2.92 Cons. EPS | 3 EPS |
25 Oct 2024 Date | | 2.95 Cons. EPS | - EPS |
Drug Manufacturers - General Industry | Healthcare Sector | Mr. Robert A. Michael CPA CEO | XMIL Exchange | US00287Y1091 ISIN |
US Country | 55,000 Employees | 15 Apr 2025 Last Dividend | - Last Split | 2 Jan 2013 IPO Date |
AbbVie Inc. is a global pharmaceutical company engaged in the discovery, development, manufacturing, and sales of a wide range of pharmaceutical products. Incorporated in 2012 and headquartered in North Chicago, Illinois, AbbVie focuses on addressing some of the world's most complex and critical health issues through its innovative medicines and therapies. In addition to its stand-alone operations, the company collaborates with several other leading institutions, including Calico Life Sciences LLC, REGENXBIO Inc., Janssen Biotech, Inc., Genentech, Inc., and Tentarix Biotherapeutics, LP. These collaborations aim to enhance AbbVie's research and development capabilities, particularly in the areas of oncology and immunology.